{"id":"insulin-humulin-nph","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting human insulin formulation where protamine is added to slow absorption and extend duration of action. It works by mimicking endogenous insulin's effects on glucose metabolism, promoting cellular glucose uptake, glycogen synthesis, and inhibiting gluconeogenesis. The protamine suspension allows for a slower onset and longer duration compared to regular insulin, making it suitable for basal insulin coverage in diabetes management.","oneSentence":"Insulin Humulin NPH is a human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:19.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT06999551","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.","status":"NOT_YET_RECRUITING","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2025-07-01","conditions":"Diabetes Mellitus","enrollment":60},{"nctId":"NCT05461365","phase":"PHASE3","title":"Intranasal Insulin for COVID-19-related Smell Loss","status":"COMPLETED","sponsor":"Universidad Panamericana","startDate":"2021-01-04","conditions":"Anosmia, Smell Loss, Paraosmia","enrollment":27},{"nctId":"NCT02967224","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":705},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT04501250","phase":"NA","title":"Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-10-23","conditions":"Pharmacokinetics, Bioequivalence","enrollment":52},{"nctId":"NCT02634528","phase":"PHASE1","title":"Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal","status":"COMPLETED","sponsor":"Julphar Gulf Pharmaceutical Industries","startDate":"2016-11-16","conditions":"Diabetes Mellitus","enrollment":85},{"nctId":"NCT04012775","phase":"PHASE3","title":"Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-04-20","conditions":"Diabetes Mellitus, Type 2","enrollment":201},{"nctId":"NCT03507829","phase":"PHASE3","title":"Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-11-21","conditions":"Hyperglycemia","enrollment":263},{"nctId":"NCT01680185","phase":"PHASE3","title":"Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-08","conditions":"Hyperglycemia","enrollment":85},{"nctId":"NCT02302716","phase":"PHASE3","title":"A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT00574405","phase":"NA","title":"Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy","status":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2005-04","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT01486966","phase":"PHASE4","title":"Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2011-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT00474045","phase":"PHASE3","title":"Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":470},{"nctId":"NCT00658099","phase":"","title":"Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":699},{"nctId":"NCT00593255","phase":"PHASE4","title":"Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-07","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":220},{"nctId":"NCT00071448","phase":"PHASE3","title":"Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":378},{"nctId":"NCT00715351","phase":"","title":"Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":342},{"nctId":"NCT00715780","phase":"","title":"Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1667},{"nctId":"NCT00665808","phase":"","title":"Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During \"Real-life\" Usage in Germany","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":8125},{"nctId":"NCT02631928","phase":"PHASE1","title":"Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III","status":"COMPLETED","sponsor":"Julphar Gulf Pharmaceutical Industries","startDate":"2016-02","conditions":"Diabetes Mellitus","enrollment":73},{"nctId":"NCT00660374","phase":"PHASE2","title":"Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01223131","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-02","conditions":"Type 1 Diabetes Mellitus","enrollment":162},{"nctId":"NCT00941369","phase":"PHASE4","title":"Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":345},{"nctId":"NCT00949442","phase":"PHASE4","title":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00993473","phase":"PHASE3","title":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 1 Diabetes Mellitus","enrollment":125},{"nctId":"NCT01500850","phase":"PHASE4","title":"Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2011-10","conditions":"Insulin-requiring Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT00659477","phase":"PHASE4","title":"Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 2","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin Humulin® NPH","genericName":"Insulin Humulin® NPH","companyName":"Geropharm","companyId":"geropharm","modality":"Biologic","firstApprovalDate":"","aiSummary":"Insulin Humulin NPH is a human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}